A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells

References

• Yuan ZQ, Chen WL, You BG, et al. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor. J Control Release. 2017;268:198–211. doi:10.1016/j.jconrel.2017.10.02529061511
   PubMed Web of Science ®Google Scholar
• Li Y, Xuan J, Song Y, et al. Nanoporous glass integrated in volumetric bar-chart chip for point-of-care diagnostics of non-small cell lung cancer. ACS Nano. 2015;10(1):1640–1647. doi:10.1021/acsnano.5b0735726690745
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Yabroff KR, Mariotto AB, Zeruto C, Tran Q, Warren JL. Antineoplastic treatment of advanced-stage non-small-cell lung cancer: treatment, survival, and spending (2000 to 2011). J Clin Oncol. 2017;35(5):529–535. doi:10.1200/JCO.2016.69.416628045621
   PubMed Web of Science ®Google Scholar
• Miao L, Guo S, Zhang J, Kim WY, Huang L. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv Funct Mater. 2014;24(42):6601–6611. doi:10.1002/adfm.20140107625395922
   PubMed Web of Science ®Google Scholar
• Kroep JR, Giaccone G, Tolis C, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer. 2000;83(8):1069–1076. doi:10.1054/bjoc.2000.139910993656
   PubMed Web of Science ®Google Scholar
• Baykara M, Coskun U, Berk V, et al. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev. 2012;13(10):5119–5124. doi:10.7314/apjcp.2012.13.10.511923244121
   PubMedGoogle Scholar
• Kroep JR, Smit EF, Giaccone G, et al. Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2006;58(4):509–516. doi:10.1007/s00280-006-0191-z16523337
   PubMed Web of Science ®Google Scholar
• Shord SS, Faucette SR, Gillenwater HH, et al. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003;51(4):328–336. doi:10.1007/s00280-002-0560-112721761
   PubMed Web of Science ®Google Scholar
• Fogli S, Danesi R, De Braud F, et al. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol. 2001;12(11):1553–1559. doi:10.1023/a:101313341594511822754
   PubMed Web of Science ®Google Scholar
• Shim G, Kim MG, Kim D, Park JY, Oh YK. Nanoformulation-based sequential combination cancer therapy. Adv Drug Deliv Rev. 2017;115:57–81. doi:10.1016/j.addr.2017.04.00328412324
   PubMed Web of Science ®Google Scholar
• Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306–332. doi:10.1016/j.jconrel.2017.08.03328844756
   PubMed Web of Science ®Google Scholar
• Gesto DS, Cerqueira NM, Fernandes PA, Ramos MJ. Gemcitabine: a critical nucleoside for cancer therapy. Curr Med Chem. 2012;19(7):1076–1087. doi:10.2174/09298671279932068222257063
   PubMed Web of Science ®Google Scholar
• Vitorino C, Almeida J, Gonçalves LM, Almeida AJ, Sousa JJ, Pais AA. Co-encapsulating nanostructured lipid carriers for transdermal application: from experimental design to the molecular detail. J Control Release. 2013;167(3):301–314. doi:10.1016/j.jconrel.2013.02.01123454133
   PubMed Web of Science ®Google Scholar
• Scioli Montoto S, Sbaraglini ML, Talevi A, et al. Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: physicochemical characterization and in vitro/in vivo evaluation. Colloids Surf B. 2018;167:73–81. doi:10.1016/j.colsurfb.2018.03.052
   PubMed Web of Science ®Google Scholar
• Li X, Jia X, Niu H. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. Int J Nanomedicine. 2018;13:4107–4119. doi:10.2147/IJN.S16392930034236
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143–161. doi:10.1016/j.nano.2015.09.00426410277
   PubMed Web of Science ®Google Scholar
• Yang Q, Li L, Sun W, Zhou Z, Huang Y. Dual stimuli-responsive hybrid polymeric nanoparticles self-assembled from POSS-based starlike copolymer-drug conjugates for efficient intracellular delivery of hydrophobic drugs. ACS Appl Mater Interfaces. 2016;8(21):13251–13261. doi:10.1021/acsami.6b0240327167898
   PubMed Web of Science ®Google Scholar
• Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials. 2016;85:152–167. doi:10.1016/j.biomaterials.2016.01.06126871891
   PubMed Web of Science ®Google Scholar
• Hu YW, Du YZ, Liu N, et al. Selective redox-responsive drug release in tumor cells mediated by chitosan based glycolipid-like nanocarrier. J Control Release. 2015;206:91–100. doi:10.1016/j.jconrel.2015.03.01825796347
   PubMed Web of Science ®Google Scholar
• Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev. 2012;64(9):866–884. doi:10.1016/j.addr.2012.01.02022349241
   PubMed Web of Science ®Google Scholar
• Deng B, Ma P, Xie Y. Reduction-sensitive polymeric nanocarriers in cancer therapy: a comprehensive review. Nanoscale. 2015;7(30):12773–12795. doi:10.1039/c5nr02878g26176593
   PubMed Web of Science ®Google Scholar
• Liu X, Wu M, Hu Q, et al. Redox-activated light-up nanomicelle for precise imaging-guided cancer therapy and real-time pharmacokinetic monitoring. ACS Nano. 2016;10(12):11385–11396. doi:10.1021/acsnano.6b0668828024380
   PubMed Web of Science ®Google Scholar
• Chi Y, Yin X, Sun K, et al. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J Control Release. 2017;261:113–125. doi:10.1016/j.jconrel.2017.06.02728666726
   PubMed Web of Science ®Google Scholar
• Koh YW, Lee SJ, Park SY. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters. Lung Cancer. 2017;104:31–37. doi:10.1016/j.lungcan.2016.12.00328212997
   PubMed Web of Science ®Google Scholar
• Pawar S, Vavia P. Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin. J Drug Target. 2015;24(1):68–79. doi:10.3109/1061186X.2015.105557226152812
   PubMed Web of Science ®Google Scholar
• Kumar P, Tambe P, Paknikar KM, Gajbhiye V. Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: a comparative study. Colloids Surf B Biointerfaces. 2017;156:203–212. doi:10.1016/j.colsurfb.2017.05.03228531877
   PubMed Web of Science ®Google Scholar
• Pawar SK, Badhwar AJ, Kharas F, Khandare JJ, Vavia PR. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery. Int J Pharm. 2012;436(1–2):183–193. doi:10.1016/j.ijpharm.2012.05.07822721850
   PubMedGoogle Scholar
• Liang Y, Tian B, Zhang J, et al. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer. Int J Nanomedicine. 2017;12:1699–1715. doi:10.2147/IJN.S12126228280336
   PubMed Web of Science ®Google Scholar
• Tian B, Ding Y, Han J, Zhang J, Han Y, Han J. N-Acetyl-D-glucosamine decorated polymeric nanoparticles for targeted delivery of doxorubicin: synthesis, characterization and in vitro evaluation. Colloids Surf B Biointerfaces. 2015;130:246–254. doi:10.1016/j.colsurfb.2015.04.01925921641
   PubMed Web of Science ®Google Scholar
• Lotfy HM, Hegazy MA, Rezk MR, Omran YR. Comparative study of novel versus conventional two-wavelength spectrophotometric methods for analysis of spectrally overlapping binary mixture. Spectrochim Acta a Mol Biomol Spectrosc. 2015;148:328–337. doi:10.1016/j.saa.2015.04.00425909908
   PubMed Web of Science ®Google Scholar
• Saad AS. Novel spectrophotometric method for selective determination of compounds in ternary mixtures (dual wavelength in ratio spectra). Spectrochim Acta a Mol Biomol Spectrosc. 2015;147:257–261. doi:10.1016/j.saa.2015.03.09525847787
   PubMed Web of Science ®Google Scholar
• Musialik M, Kuzmicz R, Pawłowski TS, Litwinienko G. Acidity of hydroxyl groups: an overlooked influence on antiradical properties of flavonoids. J Org Chem. 2009;74(7):2699–2709. doi:10.1021/jo802716v19275193
   PubMed Web of Science ®Google Scholar
• Yin S, Huai J, Chen X, et al. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 2015;26:274–285. doi:10.1016/j.actbio.2015.08.02926300335
   PubMed Web of Science ®Google Scholar
• Yin T, Wu Q, Wang L, Yin L, Zhou J, Huo M. Well-defined redox-sensitive polyethene glycol-paclitaxel prodrug conjugate for tumor-specific delivery of paclitaxel using octreotide for tumor targeting. Mol Pharm. 2015;12(8):3020–3031. doi:10.1021/acs.molpharmaceut.5b0028026086430
   PubMedGoogle Scholar
• Lakshmipriya A, Chaudhary M, Mogurampelly S, Klein ML, Suryaprakash N. The intramolecular hydrogen bonding appetency for conformational penchants in oxalohydrazide fluoro derivatives: NMR, MD, QTAIM and NCI studies. J Phys Chem A. 2018;122(10):2703–2713. doi:10.1021/acs.jpca.8b0091329488767
   PubMed Web of Science ®Google Scholar
• Kanda S, Goto K, Shiraishi H, et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Ann Oncol. 2016;27:2242–2250. doi:10.1093/annonc/mdw41627765756
   PubMed Web of Science ®Google Scholar
• Quoix E, Lena H, Losonczy G, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17(2):212–223. doi:10.1016/S1470-2045(15)00483-026727163
   PubMed Web of Science ®Google Scholar
• Houdaihed L, Evans JC, Allen C. Codelivery of paclitaxel and everolimus at the optimal synergistic ratio: a promising solution for the treatment of breast cancer. Mol Pharmaceut. 2018;15(9):3672–3681. doi:10.1021/acs.molpharmaceut.8b00217
   PubMed Web of Science ®Google Scholar
• Lu ZR, Qiao P. Drug delivery in cancer therapy, quo vadis? Mol Pharmaceut. 2018;15(9):3603–3616. doi:10.1021/acs.molpharmaceut.8b00037
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Szoka FC Jr. Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev. 2013;65(1):80–88. doi:10.1016/j.addr.2012.09.03823036224
   PubMed Web of Science ®Google Scholar
• Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38. doi:10.1016/j.addr.2018.07.00730009886
   PubMed Web of Science ®Google Scholar